Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel

BACKGROUND: TP53 mutations have been associated with resistance to anthracyclines but not to taxanes in breast cancer patients. The MDM2 promoter single nucleotide polymorphism (SNP) T309G increases MDM2 activity and may reduce wild-type p53 protein activity. Here, we explored the predictive and pro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chrisanthar, Ranjan, Knappskog, Stian, Løkkevik, Erik, Anker, Gun, Østenstad, Bjørn, Lundgren, Steinar, Risberg, Terje, Mjaaland, Ingvil, Skjønsberg, Gudbrand, Aas, Turid, Schlichting, Ellen, Fjösne, Hans E., Nysted, Arne, Lillehaug, Johan Richard, Lønning, Per Eystein
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2011
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3083424/
https://ncbi.nlm.nih.gov/pubmed/21556366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0019249
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados